Delcath Systems (DCTH) Stock Price, News & Analysis

Company Overview

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Key Stats

• Today's Range: $9.87 to $10.29
• 50-Day Range: $10.01 to $16.87
• 52-Week Range: $7.17 to $18.23
• Volume: 1.13 million shs
• Average Volume: 926,661 shs
• Market Capitalization: $350.15 million
• P/E Ratio: 200.20
• Dividend Yield: N/A
• Price Target: $24.50
• Consensus Rating: Buy

Delcath Systems Stock Analysis - MarketRank™

Delcath Systems scored higher than 60% of companies evaluated by MarketBeat, and ranked 392nd out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Delcath Systems has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Delcath Systems has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Delcath Systems are expected to grow in the coming year, from ($0.79) to ($0.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Delcath Systems is 200.20, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.86.

Price to Earnings Ratio vs. Sector

The P/E ratio of Delcath Systems is 200.20, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.03.

Price to Book Value per Share Ratio

Delcath Systems has a P/B Ratio of 3.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.23% of the outstanding shares of Delcath Systems have been sold short.

Short Interest Ratio / Days to Cover

Delcath Systems has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Delcath Systems has recently increased by 37.11%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Delcath Systems does not currently pay a dividend.

Dividend Growth

Delcath Systems does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.23% of the outstanding shares of Delcath Systems have been sold short.

Short Interest Ratio / Days to Cover

Delcath Systems has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Delcath Systems has recently increased by 37.11%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 0.77

News Sentiment

Delcath Systems has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Delcath Systems this week, compared to 3 articles on an average week.

Search Interest

13 people have searched for DCTH on MarketBeat in the last 30 days. This is an increase of 550% compared to the previous 30 days.

MarketBeat Follows

3 people have added Delcath Systems to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Delcath Systems insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.40% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.12% of the stock of Delcath Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DCTH Stock Analysis - Frequently Asked Questions

How have DCTH shares performed this year?

Delcath Systems' stock was trading at $12.04 at the beginning of the year. Since then, DCTH shares have decreased by 16.9% and is now trading at $10.01.

How were Delcath Systems' earnings last quarter?

Delcath Systems, Inc. (NASDAQ:DCTH) announced its quarterly earnings results on Wednesday, August, 6th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.02 by $0.05. The company had revenue of $24.16 million for the quarter, compared to analysts' expectations of $22.84 million. Delcath Systems had a trailing twelve-month return on equity of 6.91% and a net margin of 3.18%.
Read the conference call transcript.

When did Delcath Systems' stock split?

Delcath Systems shares reverse split before market open on Tuesday, October 22nd 2019.The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Who are Delcath Systems' major shareholders?

Top institutional shareholders of Delcath Systems include Geode Capital Management LLC (2.02%), Palisades Investment Partners LLC (0.78%), Simplify Asset Management Inc. (0.31%) and Los Angeles Capital Management LLC (0.28%). Insiders that own company stock include Gil Aharon, Rosalind Advisors, Inc, Gerard J Michel, Vojo Vukovic, John Purpura, Sandra Pennell and John Richard Sylvester.
View institutional ownership trends.

How do I buy shares of Delcath Systems?

Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Delcath Systems own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Delcath Systems investors own include Predictive Oncology (POAI), Ford Motor (F), JPMorgan Chase & Co. (JPM), Zomedica (ZOM), Wells Fargo & Company (WFC), Wayfair (W) and Bank of America (BAC).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 8/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:DCTH
• CIK: 872912
• Web: delcath.com
• Phone: 212-489-2100
• Fax: 212-489-2102
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Delcath Systems: $24.50
• High Price Target: $31.00
• Low Price Target: $21.00
• Potential Upside/Downside: +144.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.05
• Trailing P/E Ratio: 200.20
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.39 million
• Net Margins: 3.18%
• Pretax Margin: 4.18%
• Return on Equity: 6.91%
• Return on Assets: 5.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.88
• Quick Ratio: 14.61

Sales & Book Value

• Annual Sales: $37.21 million
• Price / Sales: 9.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.00 per share
• Price / Book: 3.34

Miscellaneous

• Outstanding Shares: 34,980,000
• Free Float: 28,894,000
• Market Cap: $350.15 million
• Optionable: Optionable
• Beta: 0.82